RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs

Core Insights - RetinalGenix Technologies, Inc. has signed a laboratory lease agreement with MBC BioLabs to enhance the development of its therapies for neurodegenerative and retinal diseases [1][4] - The new facility will support the advancement of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform and the repurposing of existing drugs for conditions like dementia and macular degeneration [3][4] Company Developments - The laboratory is equipped with advanced scientific equipment and is strategically located near Charles River Laboratories, facilitating in vivo animal research studies [2] - RetinalGenix is focusing on repurposing FDA-approved therapeutics for new indications, leveraging patents for legacy drugs that have been on the market for over 30 years [3][4] - The company is expanding its clinical study approvals to include multiple practices, aiming to accelerate the development of its platform [4] Collaborations and Leadership - RetinalGenix is in discussions for potential collaboration with Dr. Anatoly Dritschilo, a notable figure in radiation oncology and molecular radiation biology [5] - Dr. Fred Chasalow, a special consultant for therapeutics, will oversee laboratory activities at MBC BioLabs, bringing significant expertise in steroid discovery and neurohormone research [6] About MBC BioLabs - MBC BioLabs supports biotech startups by providing state-of-the-art lab space and access to extensive equipment, having helped launch over 350 companies since 2013 [7] About RetinalGenix Technologies Inc. - RetinalGenix is dedicated to revolutionizing early disease detection and improving patient outcomes across various diseases, including Alzheimer's and Parkinson's [8][9] - The company integrates genetic screening, advanced imaging, and therapeutic development, positioning itself as a leader in precision medicine [9]